Direkt zum Inhalt
Merck
  • A pituitary adenoma secreting follicle-stimulating hormone with ovarian hyperstimulation: treatment using a gonadotropin-releasing hormone antagonist.

A pituitary adenoma secreting follicle-stimulating hormone with ovarian hyperstimulation: treatment using a gonadotropin-releasing hormone antagonist.

Fertility and sterility (2011-11-29)
Heraldo Mendes Garmes, Oswaldo Rocha Grassiotto, Yvens Barbosa Fernandes, Luciano de Souza Queiroz, José Vassalo, Daniel Minutti de Oliveira, Cristina Laguna Benetti-Pinto
ZUSAMMENFASSUNG

To describe the management of a patient with a pituitary adenoma secreting follicle-stimulating hormone (FSH) associated with ovarian hyperstimulation who was treated with a gonadotropin-releasing hormone (GnRH) antagonist. Case report. University teaching hospital. A woman of reproductive age with secondary amenorrhea and ovarian hyperstimulation due to a pituitary adenoma secreting FSH, which persisted after transsphenoidal surgery. Clinical treatment with a GnRH antagonist. A decrease in serum estradiol levels. During the treatment period, ovarian hyperstimulation decreased as shown by a reduction in estradiol levels and an improvement in the patient's clinical condition and in the ultrasonography parameters. The GnRH antagonist was found to be effective for the short-term treatment of ovarian hyperstimulation secondary to a pituitary adenoma secreting FSH, thus representing a therapeutic option that should be taken into consideration in such cases.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Ganirelix acetate salt, ≥95% (HPLC)